title: Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically.
abstract: We compared the features of 17 cases of atypical chronic lymphocytic leukemia (aCLL) with those of a clinical control group of 24 cases of CLL. Quantitative flow cytometric data, available for 12 cases, were compared with an immunophenotypic control group of 58 cases using a relative fluorescence indexfor CD5, CD23, CD79b, and surface immunoglobulin light chain (sIg). Compared with the clinical control group, patients with aCLL had a higher mean WBC count and a lower platelet count. Patients with aCLL had a significantly higher probability of disease progression. Compared with an immunophenotypic control group of 58 CLL cases, 12 cases of aCLL demonstrated significantly higher expression of CD23. There was no significant difference in expression of sIg, CD79b, or CD5 between the groups. CD38 expression was noted in only 1 (9%) of 11 tested cases; 2 (18%) of 11 cases had trisomy 12. aCLL can be distinguished from typical CLL morphologically, clinically, and immunophenotypically. Atypical morphologic features in CLL seem to be a marker of aggressive clinical behavior.
authors.affiliation: Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, OH 44106, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Frater
authors.forename: K F
authors.initials: KF
authors.lastname: McCarron
authors.forename: J P
authors.initials: JP
authors.lastname: Hammel
authors.forename: J L
authors.initials: JL
authors.lastname: Shapiro
authors.forename: M L
authors.initials: ML
authors.lastname: Miller
authors.forename: R R
authors.initials: RR
authors.lastname: Tubbs
authors.forename: J
authors.initials: J
authors.lastname: Pettay
authors.forename: E D
authors.initials: ED
authors.lastname: Hsi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism; D019938:Cyclin D1 / Q000378:metabolism; D017931:DNA Primers / Q000737:chemistry; D004273:DNA, Neoplasm / Q000032:analysis; D018450:Disease Progression; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007124:Immunoenzyme Techniques; D007147:Immunoglobulin Light Chains / Q000378:metabolism; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D015463:Leukemia, Prolymphocytic / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction
chemical_list: D015703:Antigens, CD; D017931:DNA Primers; D004273:DNA, Neoplasm; D007147:Immunoglobulin Light Chains; D019938:Cyclin D1